CD274 and esophageal squamous cell carcinoma: Therefore, our results provide novel insights into the dysregulation of PD-L1 in the ESCC microenvironment and demonstrate circNF1 as a promising immune-response biomarker for ESCC and a therapeutic target for synergizing the efficacy of PD-L1 blockade.